Featured Story bestbrk / iStock / Getty ImagesEnzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new ...

Featured Story BioCentury & Getty ImagesGetting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable ...

Emerging Company Profile BioCentury & Getty ImagesValo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology ...

Translation In Brief BioCentury & Getty ImagesAustralian researchers uncover perlecan’s role in the tumor stroma

An Australian team has uncovered perlecan as the latest in a growing list of new therapeutic targets in the tumor stroma, and the molecule may be playing a role in pancreatic tumor invasiveness. In a ...

Translation In Brief BioCentury & Getty ImagesCold Spring Harbor team finds off-target activity can drive antitumor effects

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting ...

Translation In Brief BioCentury & Getty ImagesDNA trumps protein in Huntington onset

Two independent studies from former Teva CSO Michael Hayden and a Boston-based consortium suggest long, uninterrupted stretches of DNA repeats -- not the amino acids they encode -- could be the key to ...

Distillery Therapeutics Inhibition of G9A and DNMT methyltransferases in bladder cancer

DISEASE CATEGORY: Cancer INDICATION: Bladder cancer Dual inhibition of G9A and DNMT methyltransferases, in combination with cisplatin and anti-programmed cell death 1 ligand 1 (PD-L1), could help to ...

Distillery Therapeutics Peptide-macrocycle conjugates for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Hydroquinone macrocycle-peptide conjugates targeting CD51/CD61 could treat breast cancer by trapping polyamines, Read the full 163 word article

Distillery Therapeutics Preventing metastasis in TNBC with liposome-delivered TRAIL

DISEASE CATEGORY: Cancer INDICATION: Breast Cancer Liposomes formulated to display the apoptosis inducer TRAIL Read the full 137 word article

Distillery Therapeutics Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer Delivering chemotherapies through conjugation to tumor-targeted albumin could treat breast and colorectal cancers. Read the full ...

Distillery Therapeutics CDK11B as a new cancer target

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; pancreatic cancer; breast cancer Inhibiting CDK11B, a kinase involved in cellular processes including Read the full 170 word article

Distillery Therapeutics CXCL10-CXCR3 axis inhibition to block brain metastasis from melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibiting the chemoattractant CXCL10 or its receptor CXCR3 could prevent melanoma from forming Read the full 164 word article

Distillery Therapeutics ROS1 and pan-NTRK inhibitor for NSCLC resistant to Xalkori

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) A dual ROS1 and pan-NTRK inhibitor from Daiichi Sankyo Co. Ltd. could treat Xalkori crizotinib-resistant Read the full 229 word ...

Distillery Therapeutics Perlecan identified as new tumor stroma target

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Depleting perlecan, a protein deposited in the tumor stroma by Read the full 159 word article

Distillery Therapeutics DNM1L identified as pancreatic cancer target

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting DNM1L, a GTPase involved Read the full 90 word article

Distillery Therapeutics S100A9 could normalize metabolic imbalances from insulin deficiency

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Promoting expression of S100A9, a plasma protein induced by Read the full 126 word article

Distillery Therapeutics SMPD1 gene therapy for Niemann-Pick disease type A

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Metabolic SMPD1, a sphingomyelinase, encoded in viral vector could treat Niemann-Pick disease type A. Read the full 168 word article

Distillery Therapeutics Treating antibiotic-resistant Gram-negative infection with stapled antimicrobial peptides

DISEASE CATEGORY: Infectious disease INDICATION: Gram-negative bacterial infection; sepsis Stapled antimicrobial peptides could treat Read the full 127 word article

Distillery Therapeutics A mAb blocking IL-1 co-receptor for inflammatory, autoimmune diseases

DISEASE CATEGORY: Inflammation; autoimmune disease INDICATION: Inflammation; allergy; psoriasis A mAb against the IL-1 family co-receptor Read the full 147 word article

Distillery Therapeutics Agonizing GABA A receptor in peripheral neurons to treat autism

DISEASE CATEGORY: Neurology INDICATION: Autism Increasing signaling through GABA A receptors in peripheral Read the full 119 word article

Distillery Techniques Beam co-founder describes base editors with reduced RNA editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy Beam Therapeutics co-founder J. Keith Joung and colleagues described Read the full 142 word article

BioCentury Innovations ISSN 2377-3030